FoldRx launches Phase 1 study

FoldRx Pharmaceuticals Inc. of Cambridge has initiated a Phase 1 clinical study with its lead candidate, Fx-1006A, a small molecule compound with the potential to treat genetic disorders.

FoldRx is a development and discovery company focusing on first-in-class disease-modifying small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis).

Found at Mass High Tech